Faruqi & Faruqi Encourages Investors in Picard Medical to Reach Out

Written by Emily J. Thompson, Senior Investment Analyst

Source: PRnewswire

Updated: 2d ago

0mins

PMI+11.24%

Should l Buy PMI?

Source: PRnewswire

Legal Investigation: Faruq & Faruqi is investigating potential claims against Picard Medical for securities purchased between September 2, 2025, and October 31, 2025, indicating possible legal risks that could undermine investor confidence in the company.
Investor Contact Information: Investors who suffered losses during the specified period are encouraged to contact securities litigation partner Josh Wilson directly, with two provided phone numbers, reflecting the firm's commitment to supporting affected investors.
Class Action Deadline: The firm reminds investors of the April 3, 2026, deadline to seek the role of lead plaintiff in the federal securities class action against Picard Medical, emphasizing the urgency for investors to act promptly.
Market Impact: This investigation and potential class action could negatively affect Picard Medical's stock price, prompting investors to monitor developments closely to adjust their investment strategies and mitigate potential losses.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy PMI?" and start using high-conviction signals backed by rigorous historical data.

PMI

$1.88+Infinity%1D

Analyst Views on PMI

About PMI

Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Class Action Lawsuit Announced for Picard Medical Securities

2 days agoGlobenewswire

Class Action Initiation: Rosen Law Firm has announced a class action lawsuit for investors who purchased Picard Medical (NYSE American: PMI) securities between September 2 and October 31, 2025, indicating significant legal risks that may impact the company's stock performance.
Basis for Lawsuit: The lawsuit alleges that Picard Medical failed to disclose critical adverse facts regarding its business and securities trading during the class period, including a fraudulent stock promotion scheme involving social media, which could lead to investor losses.
Investor Rights Protection: Investors joining the lawsuit are not required to pay any upfront fees and can seek compensation through contingency arrangements, highlighting the law firm's commitment to protecting investor rights and potentially attracting more affected investors.
Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.

Picard Medical Faces Class Action Over Fraud Allegations

2 days agoGlobenewswire

Fraud Allegations: Robbins LLP has alerted investors that Picard Medical (PMI) is facing a class action lawsuit for allegedly being involved in a fraudulent stock promotion scheme, impacting securities transactions between September 2 and October 31, 2025, which may lead to significant investor losses.
Stock Price Crash: On October 24, 2025, Picard Medical's stock price plummeted by 70%, dropping from $13.30 to $3.99, and has since continued to decline to approximately $2.00, raising serious concerns about the company's financial health and investor confidence.
Insider Trading Investigation: The complaint alleges that insiders and affiliates used offshore or nominee accounts to facilitate coordinated share dumping, failing to disclose false rumors and artificial trading activities to investors, exacerbating stock price volatility.
Legal Action Notification: Investors are eligible to file papers by April 3, 2026, to serve as lead plaintiffs in the class action, representing other shareholders, highlighting the importance of corporate governance and the protection of shareholder rights.

Picard Medical Faces Class Action Lawsuit

2 days agoPRnewswire

Class Action Filed: Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, has initiated a class action lawsuit against Picard Medical (NYSE:PMI) and certain officers, seeking damages for investors who purchased securities between September 2 and October 31, 2025, indicating significant investor concern over potential fraud.
Fraud Allegations: The complaint alleges that Picard was involved in a fraudulent stock promotion scheme utilizing social media misinformation and impersonation of financial professionals, while insiders allegedly used offshore accounts to coordinate share dumping during price inflation, highlighting severe governance and transparency issues within the company.
Investor Action Encouraged: Affected investors are urged to apply for lead plaintiff status by April 3, 2026, suggesting that the case could have substantial implications for the company's future stock price and investor confidence, while also underscoring the legal system's role in upholding market integrity.
Law Firm Credentials: Bronstein, Gewirtz & Grossman, LLC has a strong reputation in securities fraud class actions, having recovered hundreds of millions for investors, emphasizing their expertise in restoring investor capital and ensuring corporate accountability, which may attract more investors to join the lawsuit.

Multiple Companies Face Class Action Lawsuits

2 days agoGlobenewswire

Richtech Robotics Class Action: Richtech Robotics Inc. is facing allegations of making false statements during the class period from January 27 to January 29, 2026, misleading investors about the company's business prospects, with a lead plaintiff deadline set for April 3, 2026.
Picard Medical Allegations: Picard Medical, Inc. is accused of being involved in a fraudulent stock promotion scheme from September 2 to October 31, 2025, which misled shareholders, and investors must file for lead plaintiff status by April 3, 2026.
Plug Power Misrepresentation: Plug Power, Inc. is under scrutiny for overstating the availability of funds related to a DOE loan during the period from January 17 to November 13, 2025, leading to misleading expectations about future projects, with a deadline for lead plaintiff applications on April 3, 2026.
Legal Consultation Reminder: The Law Offices of Frank R. Cruz encourage investors who suffered losses during these periods to contact them for legal advice to ensure their rights are protected in the class actions.